Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$177.38 USD

177.38
211,379

+1.43 (0.81%)

Updated May 31, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific (BSX) Lags Q4 Earnings Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Insulet (PODD) closed at $286.13, marking a -1.23% move from the previous day.

Insulet (PODD) Dips More Than Broader Markets: What You Should Know

Insulet (PODD) closed the most recent trading day at $289.70, moving -0.68% from the previous trading session.

Insulet (PODD) Gains As Market Dips: What You Should Know

Insulet (PODD) closed at $292.38 in the latest trading session, marking a +1.11% move from the prior day.

Insulet (PODD) Stock Sinks As Market Gains: What You Should Know

Insulet (PODD) closed the most recent trading day at $305.89, moving -0.13% from the previous trading session.

Insulet (PODD) Gains As Market Dips: What You Should Know

Insulet (PODD) closed the most recent trading day at $296.27, moving +1.35% from the previous trading session.

Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise

Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.

Is Nuveen ESG MidCap Growth ETF (NUMG) a Strong ETF Right Now?

Smart Beta ETF report for NUMG

Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up

Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Insulet (PODD) Q3 Earnings and Revenues Beat Estimates

Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 7th

GIII, PODD and LU have been added to the Zacks Rank #5 (Strong Sell) List on October 7, 2022.

3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio

Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.

Insulet (PODD) to Expand Base in Malaysia With New Facility

The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.

Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow

Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.

Insulet (PODD) Tops Q1 Earnings and Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

Rimmi Singhi headshot

Refresh Your Portfolio by Dumping These 5 Toxic Stocks

Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.

Insulet (PODD) Down 1.5% Since Last Earnings Report: Can It Rebound?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.